Arizona Cannabinoid Supplement Firm Agrees To Stop After Acknowledging 34 False Claims
After 13 Months Of Investigation, Litigation, FTC Nets $30,538 In Consumer Redress
Executive Summary
Arizona CBD marketer Kushly Industries is ordered to no longer make disease claims for products without competent and reliable scientific evidence. Settlement lists 16 examples of claims but order in US district court identifies 32 claims the firm acknowledged it used in advertising.
You may also be interested in...
‘Inactive’ Label Doesn’t Make Cannabinoids Less Active Or Clear Their Use In OTC Drugs In US
FDA warns BioLyte Laboratories and Honest Globe about making OTC drugs with cannabinoids. Firms also advised about GMP problems and that labeling cannabinoids as inactive ingredients doesn’t make their use compliant.
FTC Targets Supplement Firm In Administrative Proceeding After Contempt Complaint Fails
A ruling in Maine federal court questions whether FTC could show firms made claims a product labeled as a supplement “cures, mitigates, or treats any disease." But agency's administrative complaint includes the same phrase as a stipulation among the penalties it would order.
Supreme Court Slays POM Wonderful's Appeal Of FTC Order
The high court denies the firm's writ of certiorari to review an appellate 2015 ruling largely upholding a 2013 FTC order on claims made for POM Wonderful 100% Pomegranate Juice and POMx pills and liquid supplements.